Child and adolescent schizophrenia: pharmacological approaches (Q56675062)

Expert Opinion on Pharmacotherapy

Europe PubMed Central

title

Child and adolescent schizophrenia: pharmacological approaches (English)

0 references

0 references

1 reference

1 reference

Vishal Madaan

1

0 references

Yael Dvir

series ordinal

2

0 references

Daniel R Wilson

series ordinal

3

0 references

language of work or name

English

0 references

publication date

31 July 2008

0 references

number of pages

16

1 reference

based on heuristic

inferred from page(s)

published in

0 references

volume

9

0 references

issue

12

0 references

page(s)

2053-2068

0 references

cites work

Pharmacologic treatment of adolescent and child schizophrenia

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.12.2053

Antipsychotics in early onset Schizophrenia: Systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.12.2053

Child and adolescent schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.12.2053

Pubertal development and onset of psychosis in childhood onset schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.12.2053

AACAP official action. Summary of the practice parameters for the assessment and treatment of children and adolescents with schizophrenia. American Academy of Child and Adolescent Psychiatry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.12.2053

Annotation: childhood-onset schizophrenia: clinical and treatment issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.12.2053

Children with schizophrenia: clinical picture and pharmacological treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.12.2053

High rates of comorbidity are found in childhood-onset schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.12.2053

Neurocognitive profile in adolescents with early-onset schizophrenia: clinical correlates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.12.2053

Childhood-onset schizophrenia: premorbid and prodromal diagnostic and treatment histories.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.12.2053

Positive and negative symptoms in psychotic and other psychiatrically disturbed children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.12.2053

Looking for childhood-onset schizophrenia: the first 71 cases screened

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.12.2053

Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.12.2053

Treatment of early-onset schizophrenia spectrum disorders (TEOSS): demographic and clinical characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.12.2053

Childhood-onset schizophrenia: A double-blind, randomized clozapine-olanzapine comparison.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.12.2053

An open-label randomized comparison of olanzapine versus risperidone in the treatment of childhood-onset schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.12.2053

Olanzapine treatment in chronic drug-resistant childhood-onset schizophrenia: an open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.12.2053

A 1-year open-label trial of olanzapine in school-age children with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.12.2053

A prospective 12-week study of quetiapine in adolescents with schizophrenia spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.12.2053

Long-term safety, tolerability, and clinical efficacy of quetiapine in adolescents: an open-label extension trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.12.2053

A study of quetiapine: efficacy and tolerability in psychotic adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.12.2053

Experience with ziprasidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.12.2053

Pharmacodynamics of ziprasidone in children and adolescents: impact on dopamine transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.12.2053

Treatment-refractory schizophrenia in children and adolescents: an update on clozapine and other pharmacologic interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.12.2053

Childhood-onset schizophrenia: an open-label study of olanzapine in adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.12.2053

Clozapine treatment of childhood-onset schizophrenia: evaluation of effectiveness, adverse effects, and long-term outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.12.2053

Childhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.12.2053

Clozapine: its impact on aggressive behavior among children and adolescents with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.12.2053

Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.12.2053

Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.12.2053

A prospective study of hyperprolactinemia in children and adolescents treated with atypical antipsychotic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.12.2053

Olanzapine-induced diabetes in a seven-year-old boy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.12.2053

Atypical neuroleptics and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.12.2053

Can diabetes mellitus be induced by medication?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.12.2053

Diabetic ketoacidosis associated with olanzapine in an adolescent patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.12.2053

Electrocardiographic changes in children and adolescents treated with ziprasidone: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.12.2053

The relevance of prolonged QTc measurement to pediatric psychopharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.12.2053

Typical and atypical antipsychotics in adolescent schizophrenia: efficacy, tolerability, and differential sensitivity to extrapyramidal symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.12.2053

Human brain dopamine receptors in children and aging adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.12.2053

Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.12.2053

Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.12.2053

One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.12.2053

Neuroleptic malignant syndrome from aripiprazole in an agitated pediatric patient.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.12.2053

Clozapine-induced neuroleptic malignant syndrome: review and report of new cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.12.2053

Clozapine-induced agranulocytosis. Incidence and risk factors in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.12.2053

Hematological adverse events in clozapine-treated children and adolescents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.12.2053

Clozapine-induced neutropenia in children: management with lithium carbonate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.12.2053

EEG abnormalities during treatment with typical and atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.12.2053